Bortezomib for refractory antibody-mediated cardiac allograft rejection.
This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.
Eckman
Peter M
PM
Department of Medicine, University of Minnesota, USA.
Thorsgard
Marit
M
Maurer
David
D
Kim
Youngki
Y
Alloway
Rita R
RR
Woodle
E Steve
ES
D000368:Aged; D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D009202:Cardiomyopathies / Q000235:genetics / Q000601:surgery*; D005260:Female; D005434:Flow Cytometry; D006084:Graft Rejection / Q000188:drug therapy*; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D001897:Boronic Acids; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib